News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aduro Biotech Patent Upheld by USPTO



11/10/2011 6:51:19 AM

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. announces that the United States Patent and Trademark Office (USPTO) has confirmed the patentability of its U.S. Patent 7,842,289 (‘289 patent) at the successful conclusion of an ex parte reexamination proceeding initiated by Advaxis Incorporated (OTCBB: ADXS). During the proceeding, the USPTO rejected Advaxis’ assertions of invalidity, and confirmed that the claims are patentable as originally issued and without amendment. The proceeding has now completed with the issuance of Ex Parte Reexamination Certificate US 7,842,289 C1 on November 1, 2011.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES